肝脏因子在非酒精性脂肪性肝病中的作用
Role of Hepatokines in Non-alcoholic Fatty Liver Disease.
作者信息
Ke Yini, Xu Chengfu, Lin Jin, Li Youming
机构信息
Department of Rheumatology and Immunology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
出版信息
J Transl Int Med. 2019 Dec 31;7(4):143-148. doi: 10.2478/jtim-2019-0029. eCollection 2019 Dec.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases like type 2 diabetes and obesity. In recent decades, accumulating evidence has revealed that the hepatokines, proteins mainly secreted by the liver, play important roles in the development of NAFLD by acting directly on the lipid and glucose metabolism. As a member of organokines, the hepatokines establish the communication between the liver and the adipose, muscular tissues. In this review, we summarize the current understanding of the hepatokines and how they modulate the pathogenesis of metabolic disorders especially NAFLD.
摘要
非酒精性脂肪性肝病（NAFLD）与2型糖尿病和肥胖症等代谢性疾病密切相关。近几十年来，越来越多的证据表明，肝脏分泌的主要蛋白质——肝源性激素，通过直接作用于脂质和葡萄糖代谢，在NAFLD的发展中发挥重要作用。作为器官因子的一员，肝源性激素在肝脏与脂肪组织、肌肉组织之间建立了联系。在这篇综述中，我们总结了目前对肝源性激素的认识，以及它们如何调节代谢紊乱尤其是NAFLD的发病机制。
相似文献
1
Role of Hepatokines in Non-alcoholic Fatty Liver Disease.肝脏因子在非酒精性脂肪性肝病中的作用
J Transl Int Med. 2019 Dec 31;7(4):143-148. doi: 10.2478/jtim-2019-0029. eCollection 2019 Dec.
2
Hepatokines and non-alcoholic fatty liver disease.肝脏因子与非酒精性脂肪性肝病
Acta Biochim Pol. 2016;63(3):459-67. doi: 10.18388/abp.2016_1252. Epub 2016 Jun 6.
3
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism.肝源细胞因子与非酒精性脂肪性肝病：将肝脏病理生理学与代谢相联系
Biomedicines. 2021 Dec 14;9(12):1903. doi: 10.3390/biomedicines9121903.
4
Implication of hepatokines in metabolic disorders and cardiovascular diseases.肝脏因子在代谢紊乱和心血管疾病中的作用
BBA Clin. 2016 Mar 5;5:108-13. doi: 10.1016/j.bbacli.2016.03.002. eCollection 2016 Jun.
5
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.肝细胞因子：将非酒精性脂肪性肝病与胰岛素抵抗联系起来。
Nat Rev Endocrinol. 2017 Sep;13(9):509-520. doi: 10.1038/nrendo.2017.56. Epub 2017 Jun 9.
6
Hepatokines as a Molecular Transducer of Exercise.肝源细胞因子作为运动的分子转导器
J Clin Med. 2021 Jan 20;10(3):385. doi: 10.3390/jcm10030385.
7
Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.成纤维细胞生长因子 21 在脂代谢及非酒精性脂肪性肝病中的作用
Clin Chim Acta. 2019 Nov;498:30-37. doi: 10.1016/j.cca.2019.08.005. Epub 2019 Aug 13.
8
Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.HIV/HBV 患者的非酒精性脂肪性肝病——由抗逆转录病毒疗法加重的代谢失衡，并被肝肠肽/脂肪因子轴的破坏所延续。
Front Endocrinol (Lausanne). 2022 Mar 9;13:814209. doi: 10.3389/fendo.2022.814209. eCollection 2022.
9
Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.在理解脂肪细胞因子在非酒精性脂肪性肝病发病机制中的作用及其与肝脏因子的联系方面的最新进展。
Expert Rev Gastroenterol Hepatol. 2016;10(3):393-403. doi: 10.1586/17474124.2016.1110485. Epub 2015 Dec 14.
10
Hepatokine Profile in Adolescents with Polycystic Ovary Syndrome: A Case-Control Study.多囊卵巢综合征青少年的肝因子谱：一项病例对照研究。
J Clin Med. 2023 Sep 4;12(17):5744. doi: 10.3390/jcm12175744.
引用本文的文献
1
Fetuin-A Can Assess the Severity of Alcohol-Related Liver Disease.胎球蛋白-A可评估酒精性肝病的严重程度。
Medicina (Kaunas). 2025 Jun 25;61(7):1147. doi: 10.3390/medicina61071147.
2
Cgref1 is a CREB-H-regulated hepatokine that promotes hepatic lipogenesis by mediating epididymal fat insulin resistance.Cgref1是一种由CREB-H调节的肝因子，它通过介导附睾脂肪胰岛素抵抗来促进肝脏脂肪生成。
Int J Biol Sci. 2025 Mar 24;21(6):2568-2588. doi: 10.7150/ijbs.97008. eCollection 2025.
3
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.连接心血管疾病与代谢功能障碍相关脂肪性肝病（MASLD）：心脏代谢药物在MASLD治疗中的作用
Biomolecules. 2025 Feb 23;15(3):324. doi: 10.3390/biom15030324.
4
Overexpression and biophysical and functional characterization of a recombinant FGF21.重组FGF21的过表达及其生物物理和功能特性分析
Biophys Rep (N Y). 2025 Mar 12;5(1):100198. doi: 10.1016/j.bpr.2025.100198. Epub 2025 Jan 29.
5
The association between immunoinflammatory biomarkers NLR, PLR, LMR and nonalcoholic fatty liver disease: a systematic review and meta-analysis.免疫炎症生物标志物中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）与非酒精性脂肪性肝病之间的关联：一项系统评价和荟萃分析。
Clin Exp Med. 2025 Jan 15;25(1):39. doi: 10.1007/s10238-024-01539-1.
6
Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target.肝分泌因子与 MASLD：GLP1-Ras-FGF21-胎球蛋白 A 串扰作为治疗靶点。
Int J Mol Sci. 2024 Oct 8;25(19):10795. doi: 10.3390/ijms251910795.
7
Exploring endocrine FGFs - structures, functions and biomedical applications.探索内分泌成纤维细胞生长因子——结构、功能及生物医学应用
Int J Biochem Mol Biol. 2024 Aug 25;15(4):68-99. doi: 10.62347/PALK2137. eCollection 2024.
8
Epidemiology of metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的流行病学
Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50. doi: 10.3350/cmh.2024.0431. Epub 2024 Aug 19.
9
Targeted metabolomics study of fatty-acid metabolism in lean metabolic-associated fatty liver disease patients.瘦素介导的代谢相关脂肪性肝病患者脂肪酸代谢的靶向代谢组学研究
World J Gastroenterol. 2024 Jul 21;30(27):3290-3303. doi: 10.3748/wjg.v30.i27.3290.
10
Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.脑-肠-肝轴与代谢相关脂肪性肝病（MAFLD）的潜在机制：最新研究进展。
Int J Mol Sci. 2024 Mar 26;25(7):3694. doi: 10.3390/ijms25073694.
本文引用的文献
1
Changing NAFLD Epidemiology in China.中国非酒精性脂肪性肝病流行病学的变化
Hepatology. 2019 Oct;70(4):1095-1098. doi: 10.1002/hep.30848.
2
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.全球 2 型糖尿病患者非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学：系统评价和荟萃分析。
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
3
Circulating FGF21 Levels in Human Health and Metabolic Disease.循环成纤维细胞生长因子 21 水平与人类健康和代谢疾病。
Exp Clin Endocrinol Diabetes. 2020 Nov;128(11):752-770. doi: 10.1055/a-0879-2968. Epub 2019 May 20.
4
The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance.肝脏作为内分泌器官——连接非酒精性脂肪性肝病和胰岛素抵抗。
Endocr Rev. 2019 Oct 1;40(5):1367-1393. doi: 10.1210/er.2019-00034.
5
Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice.肝组织中胎球蛋白-A 的上调通过 TLR4 激活介导对乙酰氨基酚诱导的肝损伤。
Biochem Pharmacol. 2019 Aug;166:46-55. doi: 10.1016/j.bcp.2019.05.011. Epub 2019 May 8.
6
Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches.非酒精性脂肪性肝炎的无创诊断：新兴方法
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):1-3. doi: 10.1016/j.hbpd.2018.12.010. Epub 2018 Dec 28.
7
Sex Hormone-Binding Globulin Expression Correlates With Acetyl-Coenzyme A Carboxylase and Triglyceride Content in Human Liver.人肝中性激素结合球蛋白的表达与乙酰辅酶 A 羧化酶和甘油三酯含量相关。
J Clin Endocrinol Metab. 2019 May 1;104(5):1500-1507. doi: 10.1210/jc.2018-00740.
8
Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults.中国成年人中性激素结合球蛋白与非酒精性脂肪性肝病的关联
Nutr Metab (Lond). 2018 Nov 8;15:79. doi: 10.1186/s12986-018-0313-8. eCollection 2018.
9
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population.非酒精性脂肪性肝病患者的风险因素和代谢异常：非肥胖或肥胖的中国人群。
Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):45-48. doi: 10.1016/j.hbpd.2018.01.007. Epub 2018 Jan 31.
10
Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients.非酒精性脂肪性肝病是 SHBG 与糖尿病患者代谢综合征相关的影响因素。
Sci Rep. 2017 Nov 6;7(1):14532. doi: 10.1038/s41598-017-15232-9.
Zotero 插件